Figure 4. Activation of ERK and AKT pathways by GHRH agonists.

Fibroblasts were pre-starved in serum-free FibroLife medium for 24 hours, then treated with 1 μM GHRH agonists for 30 min in the absence (□) or presence (■) of 3 μM NVP-AEW541, a specific inhibitor for IGF-1 receptor. Phosphorylation levels of ERK1/2 and AKT were analyzed by western blots.